StockData

Cue Biopharma vs Nektar Therapeutics

CUE and NKTR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CUE and NKTR compare

Nektar Therapeutics is the larger company, worth 11 times as much as Cue Biopharma ($1.3B against $117M).

Cue Biopharma grew revenue faster over the last twelve months (354% versus −43.9% for Nektar Therapeutics).

Nektar Therapeutics keeps more of each dollar of sales as profit, with a net margin of −297% compared with −436% at Cue Biopharma.

Nektar Therapeutics scores higher on the StockData Score (9 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCUENKTR
Size and price
Market cap$117M$1.3B
Share price$16.12$37.27
Change, 1 year−19.5%−35.4%
Change, 5 years−96.4%−78.9%
Beta (5Y)2.342.06
Employees2963
StockData Score
Total score89 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score12 (better)
Health score55
Dividend score00
Valuation
P/S3.1× (better)23.0×
P/B50.7×1.5× (better)
FCF yield−42.8%−16.4% (better)
Growth
Revenue growth (TTM)354% (better)−43.9%
Revenue growth, 5Y average54.2% (better)−18.4%
Profitability
Gross margin–100%
Operating margin−262%−254% (better)
Net margin−436%−297% (better)
FCF margin−133% (better)−378%
Return on equity−1603%−35.1% (better)
Return on invested capital–−441%
Financial health
Debt / equity0.000.00
Current ratio1.259.00 (better)
Altman Z-score−30.71−0.89 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.6%105%
Held by insiders17.4%0.46%
Insider net buying, 12 months−$2.3M−$2.2M (better)
Short interest, % of float14.4%19.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.